S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.65 (+0.74%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.50 (+3.26%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.47 (+0.19%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.95 (+0.82%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.50 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.65 (+0.74%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.50 (+3.26%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.47 (+0.19%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.95 (+0.82%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.50 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.65 (+0.74%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.50 (+3.26%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.47 (+0.19%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.95 (+0.82%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.50 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.65 (+0.74%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.50 (+3.26%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.47 (+0.19%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.95 (+0.82%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.50 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
Log in
NASDAQ:CYCN

Cyclerion Therapeutics Stock Forecast, Price & News

$3.22
+0.24 (+8.05 %)
(As of 11/25/2020 03:59 PM ET)
Add
Compare
Today's Range
$2.92
Now: $3.22
$3.33
50-Day Range
$2.25
MA: $3.40
$7.12
52-Week Range
$1.78
Now: $3.22
$8.96
Volume30,760 shs
Average Volume440,512 shs
Market Capitalization$109.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
CUSIPN/A
CIKN/A
Phone857-327-8778
Employees94

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.51 million
Book Value$2.22 per share

Profitability

Net Income$-123,010,000.00
Net Margins-2,322.42%

Miscellaneous

Market Cap$109.36 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$3.22
+0.24 (+8.05 %)
(As of 11/25/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

How has Cyclerion Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has increased by 11.0% and is now trading at $3.22.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Cyclerion Therapeutics?

Wall Street analysts have given Cyclerion Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cyclerion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Cyclerion Therapeutics
.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Thursday, November, 5th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.03. The company had revenue of $0.40 million for the quarter. Cyclerion Therapeutics had a negative net margin of 2,322.42% and a negative return on equity of 105.55%.
View Cyclerion Therapeutics' earnings history
.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a drop in short interest in October. As of October 30th, there was short interest totaling 781,000 shares, a drop of 20.4% from the October 15th total of 980,700 shares. Based on an average daily trading volume, of 524,500 shares, the days-to-cover ratio is presently 1.5 days.
View Cyclerion Therapeutics' Short Interest
.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

Who are Cyclerion Therapeutics' key executives?

Cyclerion Therapeutics' management team includes the following people:
  • Dr. Peter M. Hecht, CEO & Director (Age 56, Pay $72.73k)
  • Dr. Mark G. Currie, Pres & Chief Scientific Officer (Age 65, Pay $317.88k)
  • Dr. Andreas Busch Ph.D., Chief Innovation Officer (Age 57, Pay $373.96k)
  • Mr. William Huyett, Chief Financial Officer (Age 64)
  • Ms. Cheryl Gault, Sr. VP and Head of Strategy & Corp. Devel.
  • Ms. Daryn Lewis, VP & Head of People
  • Dr. Christopher I. Wright, Head of Global Devel. & Chief Medical Officer
  • Ms. Anjeza Gjino, VP of Fin. & Corp. Sec.
  • Ms. Jessi Rennekamp, Associate Director of Corp. Communications
  • Mr. Christopher Winrow, Sr. Director of Clinical Devel. & Neuroscience Program Lead

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.49%), State Street Corp (1.29%), Charles Schwab Investment Management Inc. (0.56%), Morgan Stanley (0.18%), JPMorgan Chase & Co. (0.14%) and California Public Employees Retirement System (0.14%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett.
View institutional ownership trends for Cyclerion Therapeutics
.

Which major investors are selling Cyclerion Therapeutics stock?

CYCN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, State Street Corp, BlackRock Inc., and California State Teachers Retirement System. Company insiders that have sold Cyclerion Therapeutics company stock in the last year include Mark G Currie, and William Huyett.
View insider buying and selling activity for Cyclerion Therapeutics
.

Which major investors are buying Cyclerion Therapeutics stock?

CYCN stock was bought by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc., Morgan Stanley, JPMorgan Chase & Co., California Public Employees Retirement System, ExodusPoint Capital Management LP, and TD Asset Management Inc.. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch, and Mark G Currie.
View insider buying and selling activity for Cyclerion Therapeutics
.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $3.22.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $109.36 million and generates $4.51 million in revenue each year. Cyclerion Therapeutics employs 94 workers across the globe.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.